[1]
|
Kuroki, L. and Guntupalli, S.R. (2020) Treatment of Epithelial Ovarian Cancer. BMJ, 371, m3773.
https://doi.org/10.1136/bmj.m3773
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[3]
|
Siegel, R.L., Miller, K.D., Wagle, N.S., et al. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[4]
|
Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal (England), 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108
|
[5]
|
Li, J., Dowdy, S., Tipton, T., et al. (2009) HE4 as a Biomarker for Ovarian and Endometrial Cancer Management. Expert Review of Mo-lecular Diagnostics, 9, 555-566. https://doi.org/10.1586/erm.09.39
|
[6]
|
Lambin, P., Rios-Velazquez, E., Leijenaar, R., et al. (2012) Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis. Eu-ropean Journal of Cancer, 48, 441-446.
https://doi.org/10.1016/j.ejca.2011.11.036
|
[7]
|
van Timmeren, J.E., Cester, D., Tanadini-Lang, S., et al. (2020) Ra-diomics in Medical Imaging “How-To” Guide and Critical Reflection. Insights Imaging, 11, 91. https://doi.org/10.1186/s13244-020-00887-2
|
[8]
|
Yang, F., Wang, Y., Li, Q., et al. (2017) Intratumor Heterogene-ity Predicts Metastasis of Triple-Negative Breast Cancer. Carcinogenesis, 38, 900-909. https://doi.org/10.1093/carcin/bgx071
|
[9]
|
Burrell, R.A., McGranahan, N., Bartek, J., et al. (2013) The Causes and Consequences of Genetic Heterogeneity in Cancer Evolution. Nature, 501, 338-345. https://doi.org/10.1038/nature12625
|
[10]
|
Liu, J., Dang, H. and Wang, X.W. (2018) The Significance of Intertumor and Intratumor Heterogeneity in Liver Cancer. Experimental & Molecular Medicine, 50, e416. https://doi.org/10.1038/emm.2017.165
|
[11]
|
Morris, L.G., Riaz, N., Desrichard, A., et al. (2016) Pan-Cancer Anal-ysis of Intratumor Heterogeneity as a Prognostic Determinant of Survival. Oncotarget, 7, 10051-10063. https://doi.org/10.18632/oncotarget.7067
|
[12]
|
Moon, S.H., Kim, J., Joung, J.G., et al. (2019) Correlations between Metabolic Texture Features, Genetic Heterogeneity, and Mutation Burden in Patients with Lung Cancer. European Jour-nal of Nuclear Medicine and Molecular Imaging, 46, 446-454. https://doi.org/10.1007/s00259-018-4138-5
|
[13]
|
Choi, E.R., Lee, H.Y., Jeong, J.Y., et al. (2016) Quantitative Im-age Variables Reflect the Intratumoral Pathologic Heterogeneity of Lung Adenocarcinoma. Oncotarget, 7, 67302-67313. https://doi.org/10.18632/oncotarget.11693
|
[14]
|
Lambin, P., Petit, S.F., Aerts, H.J., et al. (2010) The ESTRO Breur Lecture 2009. From Population to Voxel-Based Radiotherapy: Exploiting Intra-Tumour and Intra-Organ Heterogeneity for Advanced Treatment of Non-Small Cell Lung Cancer. Radiotherapy and Oncology, 96, 145-152. https://doi.org/10.1016/j.radonc.2010.07.001
|
[15]
|
Lambin, P., Leijenaar, R.T.H., Deist, T.M., et al. (2017) Radi-omics: The Bridge between Medical Imaging and Personalized Medicine. Nature Reviews Clinical Oncology, 14, 749-762. https://doi.org/10.1038/nrclinonc.2017.141
|
[16]
|
Rizzo, S., Botta, F., Raimondi, S., et al. (2018) Radiomics: The Facts and the Challenges of Image Analysis. European Radiology Experimental, 2, Article No. 36. https://doi.org/10.1186/s41747-018-0068-z
|
[17]
|
李晶晶, 黎玉莹, 石海峰, 等. 影像组学分析在胰腺癌诊疗中的应用及研究进展[J]. 磁共振成像, 2022, 13(8): 150-153.
|
[18]
|
Li, S., Liu, J., Xiong, Y., et al. (2022) Application Values of 2D and 3D Radiomics Models Based on CT Plain Scan in Differentiating Benign from Malignant Ovarian Tumors. BioMed Research International, 2022, Article ID: 5952296.
https://doi.org/10.1155/2022/5952296
|
[19]
|
Kurman, R.J. and Shih, I.-M. (2008) Pathogenesis of Ovarian Cancer: Lessons from Morphology and Molecular Biology and Their Clinical Implications. International Journal of Gynecologi-cal Pathology, 27, 151-160.
https://doi.org/10.1097/PGP.0b013e318161e4f5
|
[20]
|
Kurman, R.J. and Shih, I.-M. (2016) The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. The American Journal of Pathology, 186, 733-747. https://doi.org/10.1016/j.ajpath.2015.11.011
|
[21]
|
Cree, I.A., White, V.A., Indave, B.I., et al. (2020) Revising the WHO Classification: Female Genital Tract Tumours. Histopathology, 76, 151-156. https://doi.org/10.1111/his.13977
|
[22]
|
Li, J., Li, X., Ma, J., et al. (2023) Computed Tomography-Based Radiomics Machine Learning Classifiers to Differentiate Type I and Type II Epithelial Ovarian Cancers. European Radiology, 33, 5193-5204.
https://doi.org/10.1007/s00330-022-09318-w
|
[23]
|
Wei, W., Liu, Z., Rong, Y., et al. (2019) A Computed Tomog-raphy-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study. Frontiers in Oncology, 9, Article No. 255.
https://doi.org/10.3389/fonc.2019.00255
|
[24]
|
Richardson, D.L., Sill, M.W., Coleman, R.L., et al. (2018) Paclitaxel with and without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncology, 4, 196-202.
https://doi.org/10.1001/jamaoncol.2017.4218
|
[25]
|
Marth, C., Reimer, D. and Zeimet, A.G. (2017) Front-Line Therapy of Advanced Epithelial Ovarian Cancer: Standard Treatment. Annals of Oncology, 28, viii36-viii39. https://doi.org/10.1093/annonc/mdx450
|
[26]
|
Bowtell, D.D., Böhm, S., Ahmed, A.A., et al. (2015) Rethinking Ovarian Cancer II: Reducing Mortality from High-Grade Serous Ovarian Cancer. Nature Reviews Cancer, 15, 668-679. https://doi.org/10.1038/nrc4019
|
[27]
|
Oliver, K.E., Brady, W.E., Birrer, M., et al. (2017) An Evaluation of Progres-sion Free Survival and Overall Survival of Ovarian Cancer Patients with Clear Cell Carcinoma versus Serous Carcinoma Treated with Platinum Therapy: An NRG Oncology/Gynecologic Oncology Group Experience. Gynecologic Oncology, 147, 243-249.
https://doi.org/10.1016/j.ygyno.2017.08.004
|
[28]
|
Li, H., Cai, S., Deng, L., et al. (2023) Prediction of Platinum Re-sistance for Advanced High-Grade Serous Ovarian Carcinoma Using MRI-Based Radiomics Nomogram. European Ra-diology, 33, 5298-5308.
https://doi.org/10.1007/s00330-023-09552-w
|
[29]
|
Verhaak, R.G., Tamayo, P., Yang, J.Y., et al. (2013) Prognos-tically Relevant Gene Signatures of High-Grade Serous Ovarian Carcinoma. Journal of Clinical Investigation, 123, 517-525.
|
[30]
|
Chang, S.J., Bristow, R.E. and Ryu, H.S. (2012) Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer. Annals of Surgical Oncology, 19, 4059-4067. https://doi.org/10.1245/s10434-012-2446-8
|
[31]
|
du Bois, A., Reuss, A., Pujade-Lauraine, E., et al. (2009) Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials: By the Ar-beitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer, 115, 1234-1244.
https://doi.org/10.1002/cncr.24149
|
[32]
|
Fagotti, A., Vizzielli, G., Fanfani, F., et al. (2013) Introduction of Staging Laparoscopy in the Management of Advanced Epithelial Ovarian, Tubal and Peritoneal Cancer: Impact on Prognosis in a Single Institution Experience. Gynecologic Oncology, 131, 341-346. https://doi.org/10.1016/j.ygyno.2013.08.005
|
[33]
|
Li, H., Zhang, R., Li, R., et al. (2021) Noninvasive Prediction of Residual Disease for Advanced High-Grade Serous Ovarian Carcinoma by MRI-Based Radiomic-Clinical Nomogram. European Radiology, 31, 7855-7864.
https://doi.org/10.1007/s00330-021-07902-0
|